Systematic review reveals multiple sexually antagonistic polymorphisms affecting human disease and complex traits

Jon Alexander Harper[1]*, Tim Janicke[2,3] and Edward H. Morrow[4]

* Corresponding author

[1]Evolution, Behaviour and Environment Group, School of Life Sciences, John Maynard Smith Building, University of Sussex, Brighton, BN1 9QG, UK.

[2]Centre d'Écologie Fonctionnelle et Évolutive, UMR 5175, CNRS, Université de Montpellier, École Pratique des Hautes Études, Montpellier, France.

[3]Applied Zoology, Technical University Dresden, Zellescher Weg 20b, 01062 Dresden, Germany.

[4]Department of Environmental and Life Sciences, Karlstad University, 651 88, Karlstad, Sweden.

Jon Alexander Harper ORCID: 0000-0002-1765-9990

Tim Janicke ORCID: 0000-0002-1453-6813

Edward H Morrow ORCID: 0000-0002-1853-7469

Short title: Systematic review of sexually antagonistic genes in human disease

Abstract

An evolutionary model for sex differences in disease risk posits that alleles conferring higher risk in one sex may be protective in the other. These sexually antagonistic (SA) alleles are predicted to be maintained at frequencies higher than expected under purifying selection against unconditionally deleterious alleles, but there are apparently no examples in humans. Discipline-specific terminology, rather than a genuine lack of such alleles, could explain this disparity. We undertook a two-stage review of evidence for SA polymorphisms in humans using search terms from (i) evolutionary biology and (ii) biomedicine. While the first stage returned no eligible studies, the second revealed 51 genes with sex-opposite effects, 22 increased disease risk or severity in one sex but protected the other. Those with net positive effects occurred at higher frequencies. None were referred to as SA. Our review reveals significant communication barriers to fields as a result of discipline-specific terminology.

148 words

Introduction

In species with separate sexes an evolutionary conflict at the level of individual genetic loci can occur, where alleles that are favoured by selection in one sex are selected against in the other (i.e intralocus sexual conflict, Parker, 1979). This sexually antagonistic (SA) form of selection is thought to be driven by differences in how the two sexes maximize their fitness and concomitant unequal variances in reproductive success. Research into SA selection has expanded recently with the recognition that it feeds into several important evolutionary processes. It is primarily thought to drive the evolution of sexual dimorphism and trait diversification (Lande, 1980; Pennell et al., 2016; Rice, 1984), including sex-biased gene expression (Ellegren and Parsch, 2007). As a potential driver of balancing selection, it has also been implicated in the maintenance of genetic variation (Connallon and Clark, 2013; Grieshop and Arnqvist, 2018) that would otherwise be eroded by directional selection. Most recently, it has been suggested that genetic variation at SA loci could contribute to the occurrence of a number of common human diseases (Morrow, 2015; Morrow and Connallon, 2013), which also show considerable variation between the sexes in terms of their prevalence, severity and age of onset (Ober et al., 2008; Rigby and Kulathinal, 2015).

Despite the interest in sexual antagonism as an evolutionary force, determining the identity of SA loci remains a major challenge (Ruzicka et al., 2020). An early empirical milestone in the field of sexual conflict was achieved by quantitative genetic studies demonstrating that genomes in a laboratory adapted population of *Drosophila melanogaster* harbour significant amounts of SA standing genetic variation (Chippindale et al., 2001; Rice, 1992). A number of other systems have shown similar results, albeit using different methods, including invertebrates and vertebrates from both lab and wild populations (Bonduriansky and Chenoweth, 2009; Foerster et al., 2007; Mills et al., 2011). With the advent of advanced genomic tools, two model systems report specific examples of SA genetic loci: in Atlantic salmon (*Salmo salar*) the VGLL3 locus (Barson et al., 2015), and in *D. melanogaster* the DDT-R locus (Rostant et al., 2015), the Ala-278-Thr polymorphism in the mitochondrial genome (Camus et al., 2015), and multiple candidate loci from a recent genome-wide association study (Ruzicka et al., 2019).

Although humans have also been shown to experience SA selection for some quantitative traits (Garver-Apgar et al., 2011; Stearns et al., 2012; Stulp et al., 2012), and there

68 are numerous reports of genetic loci with sex-specific effects (i.e. effects that differ in
69 magnitude between the sexes) on multiple complex traits or disease phenotypes (Gilks et al.,
70 2014; Winkler et al., 2015), there are apparently no clear examples of SA loci in humans, which
71 is inconsistent with theoretical expectations (Connallon and Clark, 2014). One potential
72 explanation is that sexual antagonism is a weak selective force in humans, with sexual
73 dimorphism being rather limited (Dixson, 2009; Short, 1979). This may indicate that
74 concordant selection pressures between the sexes have dominated our evolutionary history.
75 But the recent quantitative genetic studies challenge this view (Stearns et al., 2012; Stulp et
76 al., 2012), and indeed theory predicts there is an inevitability to SA loci occurring in organisms
77 with separate sexes (Connallon and Clark, 2014; Parker et al., 1972). Thus, there is a clear
78 disparity between, on the one hand, theoretical expectations and quantitative genetic
79 evidence that SA selection does occur in humans, and on the other hand, a complete lack of
80 specific examples of SA loci. All this in the context of decades of research into how individual
81 genetic variants influence disease profiles.
82 An alternative explanation for the absence of documented SA loci in humans is that
83 since biomedical science does not use the same terminology for SA effects that evolutionary
84 biology uses, there may in fact be examples that have been misclassified and therefore remain
85 hidden in the literature. For example, genetic loci with sex-specific effects are frequently
86 referred to as *sex-dependent* effects in the biomedical literature. Other terms are also used
87 for related concepts, including *sex-different* effects. Furthermore, *sex-opposite* effects (i.e. a
88 positive effect in one sex and a negative in the other) could be SA effects if the phenotype in
89 question is deleterious, as disease phenotypes often are, since they can influence an
90 individual's survival or reproductive fitness. The biomedical literature also frequently uses the
91 terms *sex* and *gender* interchangeably, with *males* and *females* more often than not referred
92 to as *men and women*, or *boys and girls* (Khramtsova et al., 2019). There is therefore ample
93 scope for discipline-specific terms to be used for describing the same concept, which may
94 hinder communication between disciplines and obscure examples of SA loci. Moreover,
95 although there has been some progress in introducing concepts from evolutionary biology
96 into the field of medicine (Nesse and Williams, 1994), those inroads have been relatively
97 recent. It is therefore likely that the concepts of (intralocus) sexual conflict and sexual
98 antagonism are not generally well known within biomedical science, and variants that may
99 have SA effects on disease risk may not be referred to as such. A secondary related hypothesis

100 is that SA effects, when discovered, are discounted as errors as they do not match
101 expectations that sex-differences in phenotype or genetic architecture are not important
102 (Clayton and Collins, 2014). As a result, that may also lead them to be misclassified or simply
103 go unreported, leading to a general publication bias.

104 For these reasons, we propose that a systematic review of the biomedical literature
105 to identify SA loci in humans requires a specific and targeted set of search terms that would
106 not normally be used within the field of evolutionary biology. We test this assumption by
107 dividing our systematic review into two stages. In the first stage, we search for papers
108 identifying specific genetic loci using terms directly relating to the concept of sexual
109 antagonism and others utilized in evolutionary biology. We supplement this search with a
110 second stage, where we develop a set of terms that we hypothesize may capture the same
111 concept as sexual antagonism within the biomedical literature, although not explicitly stated
112 as such, as well as additional terminology relating to possible alternatives for describing the
113 two sexes. From our searches we also extracted data on sex-specific effect sizes and allele
114 frequencies. We were then able to explore how effect sizes varied for the same alleles
115 between the sexes, and test the prediction that SA alleles experiencing net positive selection
116 between the sexes may achieve higher equilibrium frequencies than alleles that experience
117 more symmetric or net negative patterns of selection (Morrow and Connallon, 2013). Our
118 systematic review aims to advance our understanding of SA genes in humans, which show
119 considerable and largely unexplained diversity in sexual dimorphism for disease phenotypes
120 (Ober et al., 2006; Rigby and Kulathinal, 2015), but we also highlight how and why
121 interdisciplinary research (in this case between biology and medicine) can sometimes fail,
122 impeding scientific advances over significant periods of time.

123 Methods

124 For this systematic review we followed PRISMA guidance where possible (Moher et al., 2009).
125 PubMed (https://pubmed.ncbi.nlm.nih.gov/) was searched for articles on 2nd December 2020
126 with no time limit. The searches were carried out in two Stages, with the organism filter set
127 to human in both stages. In Stage 1, eligible studies were required to report specific genetic
128 variants or haplotypes that were referred to as sexually antagonistic or were an example of
129 intralocus sexual conflict. To achieve this, we conducted a Boolean search for articles that
130 used the terms “sexual antagonism” OR “sexually antagonistic” OR “intralocus sexual conflict”

131 AND “locus” OR “loci”, “gene” OR “snp” OR “polymorphism” OR “variant” OR “allele” in their
132 abstract or title. The Stage 1 search returned 34 articles in total (full search term in the
133 supplementary material; search output is accessible at
134 https://pubmed.ncbi.nlm.nih.gov/collections/60255050/?sort=pubdate).
135 In Stage 2, studies were required to report specific genetic variants or haplotypes in
136 humans with opposite effects in the two sexes on either complex traits, the outcome of a
137 medical intervention, or disease risk/severity. We define complex traits as likely with a
138 polygenic genetic architecture but are not directly related to a disease phenotype. In this
139 second stage search terms were specifically designed to include papers from the biomedical
140 literature that may have been missed in the first stage because they do not report their
141 findings with terms normally found within the evolutionary biology literature. Again, we
142 conducted a Boolean search for articles that used terms in their title or abstract to describe
143 an opposite or different effect in the two sexes (“sex dependent”, “sex different”, “gender-
144 dependent”, “sex AND opposite”, or “gender AND opposite”), or that capture this concept
145 with alternative words for sex ((“male AND female AND opposite” OR “men AND women AND
146 opposite” OR “boys AND girls AND opposite”) AND (“locus” OR “loci” OR “gene” OR “snp” OR
147 “polymorphism” OR “variant” OR “allele”)). Full details of the search terms used and the
148 numbers of articles returned are provided in the supplementary material. The Stage 2 search
149 returned 881 papers (Figure 1) (full search term in the supplementary material; search output
150 is accessible at https://pubmed.ncbi.nlm.nih.gov/collections/60254985/?sort=pubdate).
151 The abstracts of the papers from Stage 1 were then examined by EM and from Stage
152 2 by JH, and any papers that had the possibility of reporting an opposite effect of a specific
153 genetic locus on a complex trait, medical intervention or on disease risk/severity were
154 considered for further screening. From Stage 1, no articles passed the screening. From Stage
155 2, this screening produced a shortlist of 70 candidate papers
156 (https://pubmed.ncbi.nlm.nih.gov/collections/57906298/?sort=pubdate) Both JH and EM
157 then reviewed all the full texts of these candidate papers in detail. Papers were included in
158 the final list if they described a sex-opposite or SA effect linked to a specific genetic locus or
159 loci, and reported the effect to be statistically significant (at a P-value cut-off of <0.05). One
160 additional paper was considered from an outside source.
161



Figure 1. PRISMA flow diagram for systematic review of sexually antagonistic loci in humans.

165 We converted all reported sex-specific effects into a standard effect size (Cohen's *d*)
166 quantifying the magnitude of how a given variant affects the studied trait expressed in the
167 given sex. Specifically, Cohen's *d* was computed based on the reported descriptive statistics
168 (*N*, mean, standard error) or by conversion from other effect sizes (Odds ratio) and test
169 statistics (*F*-values, *t*-values) using formulas reported elsewhere (Borenstein, 2009; Gurevitch
170 et al., 2013, pp. 195–206; Lajeunesse, 2013). We sought information directly from the authors
171 where these metrics were not possible to extract from the papers themselves (12 authors
172 contacted, 5 responded, 3 responded with data, all later excluded as they did not fulfil the
173 criteria for eligibility). We also recorded the gene name, locus (with accession/rs number
174 where possible), trait affected and the frequency of the focal allele having the effect,
175 hereafter referred to as *effect allele frequency*. Identification for the variants were taken from
176 the studies where possible, but others necessitated searching the National Centre for
177 Biotechnology Information (NCBI) to find the Reference SNP cluster ID for the variants
178 described. Where effect allele frequencies were not reported, we used genotype frequencies
179 to calculate effect allele frequency. Not all studies reported allele or genotype frequencies
180 and so we attempted to supplement these data with allele frequencies from the 1000
181 genomes database (Auton et al., 2015), since these show a strong correlation with effect allele
182 frequencies reported in the studies reviewed (Pearson correlation: $N = 25$ $r = 0.94$, $P > 0.001$;
183 Figure S1). However, using this approach we were only able to supplement our allele
184 frequency data for one additional locus (rs7341475 in the *RELN* gene; Table 1).
185 If b_f and b_m represent the estimated effect of the focal allele in females and males
186 respectively, then positive values of b_f or b_m imply that the allele is positively associated with
187 disease expression, whereas negative values imply that the allele is negatively associated with
188 disease expression. SA alleles are therefore defined as those with opposite effects between
189 the sexes (i.e. $b_f < 0 < b_m$ or $b_m < 0 < b_f$). An evolutionary model of evolution at SA loci predicts
190 that as the magnitude of the positive effect that an SA allele has outweighs the negative
191 effect, the higher the frequency that allele can achieve (Morrow and Connallon, 2013). We
192 therefore expect a negative relationship between the ratio of positive to negative effect sizes
193 (hereafter referred to as the *effect size ratio*) and observed allele frequency. To investigate
194 this, we calculated the effect size ratio by dividing the positive standardized effect size by the
195 negative standardized effect size; when $b_f < 0 < b_m$ effect size ratio was calculated as b_m / b_f,
196 and when $b_m < 0 < b_f$ effect size ratio was calculated as b_f / b_m.

197 **Table 1. Genetic loci in humans showing sexually antagonistic effects on trait expression.** EAF, effect allele frequency (* indicates allele
198 frequency derived from 100 genomes database); M, male; F, female. Background colours denote instances where genes and/or variants
199 appear more than once in the list.
200

Trait	Gene	Locus	EAF	M Effect	M Effect SE	F Effect	F Effect SE	Reference
Complex traits								
Concentration performance score	FADS1/2	rs1535	0.672	0.2275	0.1065	-0.2394	0.1116	(Lauritzen et al., 2017)
Reading speed, number of sentences	FADS1/2	rs174448	0.642	0.5511	0.1069	-0.6074	0.1129	(Lauritzen et al., 2017)
Reading speed, number of sentences	ELOVL5	rs2397142	0.695	-0.1963	0.1042	0.2364	0.1095	(Lauritzen et al., 2017)
Reading speed, correct sentences	FADS1/2	rs174448	0.642	0.6599	0.1077	-0.3451	0.1112	(Lauritzen et al., 2017)
Speed-dating success	OPRM1	rs1799971	0.922	0.4697	0.2275	-0.53	0.2856	(Wu et al., 2016)
Speed-dating success	HTR2A	rs6311	0.418	-0.4826	0.1982	0.4702	0.1964	(Wu et al., 2016)
Waist-hip-ratio (BMI adjusted)	SIM1	rs17185536	0.76	-0.0166	0.008	0.0264	0.0067	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	NMU	rs3805389	0.28	-0.0139	0.0067	0.0261	0.006	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	GNPNAT1	rs4898764	0.53	0.0208	0.0066	-0.0165	0.0059	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	SGCZ	rs17470444	0.71	0.0345	0.0081	-0.0149	0.0068	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	IQGAP2	rs2069664	0.53	0.0244	0.0078	-0.0183	0.0067	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	SLC2A3	rs741361	0.6	0.0272	0.0079	-0.0196	0.0067	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	IRS1	rs2673140	0.38	0.022	0.0066	-0.0209	0.0059	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	TTN	rs2042995	0.23	0.0198	0.0066	-0.022	0.0078	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	RXRA	rs10881574	0.07	0.0268	0.008	-0.0191	0.0067	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	PTPRD	rs7042428	0.98	0.0244	0.0071	-0.0166	0.0063	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	CECR2	rs17809093	0.04	0.0294	0.0091	-0.024	0.0077	(Winkler et al., 2015)
Reaction time (RT) in the Stroop task, congruent condition	CHRNA5	rs3841324	0.406	-1.5421	0.3857	0.9945	0.2517	(Schneider et al., 2015)
Reaction time (RT) in the Stroop task, incongruent condition	CHRNA5	rs3841324	0.406	-1.6215	0.389	1.0215	0.2521	(Schneider et al., 2015)
Reaction time (RT) in the Negative priming task	CHRNA5	rs3841324	0.406	-1.675	0.3912	0.6299	0.247	(Schneider et al., 2015)

Borderline personality traits after maltreatment	OXTR	rs53576	0.738	-0.3429	0.0881	0.2066	0.0857	(Cicchetti et al., 2014)
Borderline personality traits after maltreatment	FKBP5	CATT haplotype	-	0.2041	0.0877	-0.195	0.0857	(Cicchetti et al., 2014)
fluid intelligence	C16orf62 (OXTR)	rs226849	0.46	-0.3949	0.1869	0.494	0.1814	(Kiy et al., 2013)
face perception	C16orf62 (OXTR)	rs226849	0.46	-0.5819	0.1909	0.3498	0.1788	(Kiy et al., 2013)
face memory	C16orf62 (OXTR)	rs226849	0.46	-0.3679	0.1864	0.3562	0.1789	(Kiy et al., 2013)
Hippocampal volume	SLC6A4	rs25531	0.39	-		-		(Price et al., 2013)
Sociopathy (in alcoholics)	SLC6A4	rs25531	0.51	-		-		(Herman et al., 2011)
systolic blood pressure S_NIGHT	PON1	rs3917542	-	-0.1047	0.0637	0.1129	0.0645	(Padmanabhan et al., 2010)
systolic blood pressure S_NIGHT	PON3	rs17884563	-	-0.1482	0.0637	0.1061	0.0645	(Padmanabhan et al., 2010)
systolic blood pressure S_CLIN	EDNRB	rs1335803	-	-0.1308	0.0637	0.1129	0.0645	(Padmanabhan et al., 2010)
diastolic blood pressure D_NIGHT	DRD1	rs265974	-	-0.1482	0.0637	0.1502	0.0646	(Padmanabhan et al., 2010)
diastolic blood pressure D_HOME	SLC4A2	rs2303933	-	-0.1482	0.0637	0.1325	0.0646	(Padmanabhan et al., 2010)
diastolic blood pressure D_CLIN	LPL	rs17410577	-	-0.1047	0.0637	0.1775	0.0647	(Padmanabhan et al., 2010)
Psychological Stress	BDNF	rs6265	0.149	-		-		(Shalev et al., 2009)
BMI standard deviation score (children)	FAS	rs2228305	0.0312	-0.552	0.2259	0.4427	0.2075	(Korner et al., 2007)
Pain sensitivity	OPRM1	rs1799971	0.8817	-		-		(Fillingim et al., 2005)
Central DBP	REN	rs6693954	0.22	-0.4444	0.2132	1.1052	0.3923	(Ljungberg et al., 2014)
Disease risk/severity								
Graves opthalmopathy in GD	PRR3	rs2074503	0.3586	0.4397	0.1682	-0.2185	0.0851	(Liu et al., 2014)
Colorectal cancer	LTA	rs1041981	0.32	-0.0722	0.0368	0.1027	0.0453	(Sainz et al., 2012)
Arterial blood pressure	PPAR	rs1801282	0.1213	-		-		(Franck et al., 2012)
Schizophrenia risk	RELN	rs7341475	0.851*	1.2396	0.2819	-0.762	0.3662	(Ovadia and Shifman, 2011)
Colon cancer survival	ESR2	(CA)n repeats	-	0.2272	0.0962	-0.2046	0.1205	(Press et al., 2011)
Schizophrenia risk	DAO	rs2070586	0.2729	0.1982	0.0888	-0.2537	0.0908	(Kim et al., 2010)

T2DM, fasting glucose	SCARB1	rs9919713	0.04	0.1865	0.0853	-0.2515	0.0697	(McCarthy et al., 2009)
Depression	SLC6A4	rs25531	0.4586	0.5404	0.2277	-0.3996	0.1859	(Sjoberg et al., 2006)
Infertility in cystic fibrosis	CFTR	rs213950	0.417931	-		-		(Morea et al., 2005)
Bone mineral density	APOE	rs429358	0.0798	-		-		(Wong et al., 2005)
Narcolepsy severity	COMT	Long allele	0.4588	1.3596	0.3878	-2.2152	0.4871	(Dauvilliers et al., 2001)
Nonsyndromic cleft lip	IMPK	rs11142081	0.863	1.2156	0.0937	-1.1161	0.0783	(Carlson et al., 2018)
Nonsyndromic cleft lip	IMPK	rs72804706	0.898	-0.816	0.0906	2.0665	0.0908	(Carlson et al., 2018)
Nonsyndromic cleft lip	IMPK	rs77590619	0.744	-0.8577	0.0904	1.2291	0.0804	(Carlson et al., 2018)
Allergy	ACP1	A* allele (CG haplotype)	-	-		-		(Gloria-Bottini et al., 2007)
Hepatitis C susceptability	IL-12B	rs3212227	0.3463	-		-		(Youssef et al., 2013)
RSV severity	IL-9	rs2069885	0.15	0.1888	0.0933	-0.2794	0.0957	(Schuurhof et al., 2010)
CV risk marker (plasma fatty acid composition)	FABP2	rs1799883	0.287	-		-		(Gastaldi et al., 2007)
Bone mineral density	NR3C1	GCAG haplotype	-	0.6854	0.3676	-0.9029	0.4311	(Peng et al., 2008)
Anxiety	NGF	rs6330	0.451	0.4562	0.18	-0.4674	0.1817	(Lang et al., 2008)
Melanoma risk	RNASEL, miR-146a	AG/AA and C haplotype	-	0.4525	0.1564	-0.3553	0.174	(Sangalli et al., 2017)

201

202 Thus, SA alleles with a greater beneficial effect will have a smaller, more negative
203 effect size ratio (<-1), while SA alleles that have a greater deleterious effect will have a larger
204 effect size ratio (>-1), up to a maximum value of 0 (positive values occur when the effect is
205 positive or negative in both sexes, but the allele would then no longer be defined as a SA
206 allele).

207 We modelled how effect allele frequency changes with effect size ratio using a
208 generalized linear model (GLM), weighted by the inverse of the variance of the effect sizes
209 such that data points with smaller variance have a higher weight, since smaller sample sizes
210 were associated with larger and more variable effect sizes (Figure S2). We initially also
211 included trait class and its interaction with effect size ratio as a fixed factor with two levels
212 (complex trait and disease trait/severity), since alleles that influence complex traits in
213 opposite directions are not necessarily under SA selection and so may not behave in the way
214 predicted, whereas alleles influencing disease traits, unless very late acting, are more likely
215 to show a closer relationship with marginal effects on fitness. As a response variable, effect
216 allele frequency is limited between 0 and 1, so we looked at allele counts to allow allele
217 frequency to vary freely. GLMs with binomial error distribution showed substantial
218 overdispersion, so we used a quasibinomial function to address this issue (Payne et al., 2018).
219 We used a Chi-squared test to infer significance of the two predictor variables and their
220 interaction. The full model indicated that the interaction term and trait class have no
221 significant effect, so that we report the fit of the reduced model which only includes effect
222 size ratio. We also subsequently modelled the data for the two trait classes (complex traits
223 and disease risk/severity) separately, again using a quasibinomial distribution function, to see
224 if the result was replicated in these smaller subsets of the data. The raw data and R script is
225 available for replicating the analyses and figures we present (Supplementary Material).

226 Results

227 The Stage 1 search found no articles that described genetic loci in humans with effects that
228 were sexually antagonistic. In contrast, the Stage 2 search identified 32 articles that described
229 variants with statistically significant sex-opposite or SA effects (Figure 1;
230 https://pubmed.ncbi.nlm.nih.gov/collections/60278165/?sort=pubdate). From the studies
231 examined, 51 SA variants were identified (Table 1), affecting 21 different complex traits (30
232 loci) and 19 disease risk/severity traits (21 loci), with a large range of effect sizes. There were

no variants affecting medical intervention traits that passed the screening process. The majority of alleles had effect sizes of similar absolute values in the two sexes, with larger effects tending to show greater differences on absolute effect size (Figure S3).

We found 22 studies provided sufficient data to allow the relationship between effect size ratio and effect allele frequency to be explored by statistical modelling. Trait class and its interaction with effect size ratio were initially included in the model but neither were found to have a significant effect (GLM: trait class dfs = 1,35, deviance = 15.5×10^3, $P = 0.965$; interaction dfs = 1,34, deviance = 1476, P = 0.989) and were therefore excluded from the subsequent model in which effect size ratio was found to relate negatively to effect allele frequency, as predicted (GLM: estimate ± SE = -1.10 ± 0.50, dfs = 1,36, deviance = 38.7×10^6, $P = 0.024$; Figure 2). For three loci there were data on effect sizes for more than one trait (Table 1), which introduced a degree of non-independence between these values in the dataset. However, resampling the data with effect sizes for only one trait for these three loci in turn and modelling these datasets in the same way (18 individual GLMs, dfs = 1,31) did not change the results qualitatively (minimum, maximum: model estimate = -1.0963, -1.0964; deviance = 38.72×10^6, 38.73×10^6; $P = 0.03618, 0.03620$).

Although the interaction term between trait type and effect size ratio was not significant we wanted to investigate whether the negative relationship between effect size ratio and effect allele frequency across all loci was repeated when the data was divided according to trait class, since while opposite effects on disease risk/severity may show a direct relationship with SA fitness effects, complex traits may or may not be experiencing SA selection, even if effects are in opposite directions in the two sexes. However, although the trends were both again negative as predicted, the generalized linear models of these smaller datasets were only marginally significant (complex traits model estimate ± SE = -1.10 ± 0.61, dfs = 1,24, deviance = 38.7 × 106, P = 0.065; disease risk/severity model estimate ± SE = -1.34 ± 0.77, dfs = 1,10, deviance = 5.14 × 104, P = 0.053; Figure S4). As for the full dataset, there was some lack of independence for the complex traits subset which contained loci with effect sizes for more than one trait. Again, resampling and modelling these datasets in the same way (18 individual glms, dfs 1, 22) did not change the results quantitatively (minimum, maximum: model estimate = -1.0960, -1.0961; deviance = 38.669×10^6, 38.675×10^6; $P = 0.07774, 0.07776$).



Figure 2. The relationship between effect allele frequency and effect size ratio. Point size varies according to the variance of effect size ratio - larger points have smaller variance and therefore a larger weighting in the model. The vertical dotted line represents the switch point between a net-negative effect of a particular locus (effect size ratio >-1) and a net positive effect (effect size ratio <-1). The blue line represents the predicted values derived from the generalized linear model fitted to the data (see Results).

Discussion

The Stage 1 literature search of our systematic review focussed on finding reports of specific genetic loci in humans with evidence for SA effects using terminology normally associated with the evolutionary concepts of sexual conflict or sexual antagonism. The Stage 2 search sought equivalent evidence, but used search terms that we anticipated would be used by scientists outside the field of evolutionary biology, who may not use the same terminology. Although the Stage 1 search did not find any examples of SA loci occurring in humans, the Stage 2 search identified 51 genetic loci across 39 studies that had ostensibly SA effects, but were not described as such. Clearly then the Stage 1 review failed to identify multiple relevant reports going back some 20 years because the terminology used in those reports did not match the conceptual framework of the search. The Stage 2 search may also be a lower limit given searches of other larger databases may also harbour further examples (see below). Although not yet validated, these reports nonetheless represent a substantial body of evidence that humans, like other organisms with separate sexes (Bonduriansky and Chenoweth, 2009), inevitably experience SA selection for a wide range of complex traits (Connallon and Clark, 2014; Garver-Apgar et al., 2011; Stearns et al., 2012; Stulp et al., 2012), as well as for a range of diseases.

A key prediction from a population genetic model of SA genetic variation is that SA alleles are expected to achieve higher equilibrium frequencies, without necessarily going to fixation, as the relative magnitude of the positive effect in one sex outweighs the negative effect in the opposite sex i.e. an increasingly negative effect size ratio (Morrow and Connallon, 2013). We found clear support for this prediction, with a negative relationship between effect size ratio and allele frequency when examining all complex traits and diseases together (Fig 2), although this relationship was only marginally significant when complex or disease trait classes were modelled separately (Fig S3). These results lend support to the view that the loci identified are genuinely experiencing SA selection, and although it is difficult to discern how selection acts on trait size in males and females for complex traits we would not expect the frequencies of disease-causing alleles to be so high under a mutation-selection balance. We were not able to look at the evolutionary history or age of these alleles due to limited information (n = 8) (Albers and McVean, 2018), it would nonetheless be valuable to examine the population dynamics of these alleles over a broad timescale.

302 The loci showed a very broad range of effect sizes, from small to very large, with a
303 generally symmetrical inverse relationship between effect size in one sex and the other
304 (Figure S2), which is generally expected, since our screening process necessarily excluded
305 studies reporting effects in the same direction across the two sexes. Nonetheless, it is striking
306 just how large some of the effects were, with very large negative effects in one sex
307 simultaneously occurring with similarly large positive effects. Larger and more variable effect
308 sizes are expected when sample sizes are small, a pattern we also found, which motivates
309 further investigation of the traits and loci included in this review to elucidate more accurate
310 estimates of real effect sizes.

311 The loci themselves fall within genes that influence a broad range of phenotypes,
312 including morphological, physiological and behavioural complex traits, and a similarly diverse
313 range of disease types, including various cancers, neurological disorders and immune system
314 processes (see Table 1). For the most part, the diseases appear to be early-acting rather than
315 late-onset, with the exception of perhaps bone mineral density. As such, it seems reasonable
316 that an allele that increases disease risk or severity in these cases will indeed have a
317 concomitant reduction in marginal fitness. Although a single large study identified several loci
318 related to BMI adjusted waist-to-hip ratio, there is generally no overall bias towards one
319 particular trait or disease class. The total number of loci is relatively small however, which
320 may limit power to identify such biases if they exist. We also did not find any examples of SA
321 loci on the X-chromosome, which may or may not be a hotspot of sexual antagonism (Fry,
322 2010; Rice, 1984; Ruzicka and Connallon, 2020). This was expected given that it is commonly
323 not included in genome-wide analyses (Wise et al., 2013), although most of the papers we
324 reviewed were candidate gene studies. Nonetheless, we anticipate further examples may be
325 identified should data from the X-chromosome be included systematically in association
326 studies.

327 We also found evidence that some traits are influenced by more than one genetic
328 variant in sex-opposite or SA ways (n=8), or that some specific variants have pleiotropic
329 effects on more than one trait or disease in a sex-opposite or SA way (n=6; see Table 1). This
330 complexity in the genetic architecture of traits or diseases may make conflict resolution
331 particularly difficult, as a change in the allele at a single genetic locus experiencing SA
332 selection may simultaneously influence multiple genes or phenotypes in both sexes in
333 divergent ways (Fitzpatrick, 2004; Pennell and Morrow, 2013). Consequently, this may explain

334 the persistence of intralocus sexual conflict at these loci. It may be that some of the remaining
335 loci also have as yet unidentified pleiotropic effects with other traits or there are as yet
336 unidentified SA loci influencing those same traits or diseases. Of the 51 variants identified, 4
337 were confirmed to be haplotypes. Such variants, consisting of two or more SNPs in linkage
338 disequilibrium having a joint effect, could also present a problem for conflict resolution, since
339 the ability of selection to act on any individual locus independent of the others in the linkage
340 block is reduced for linked loci. This issue may also extend to other single variants reported
341 here if they also occur in linkage blocks.

342 Although we have identified multiple genetic loci with either sex-opposite or SA
343 effects these are likely outnumbered by those with either sex-specific (same direction but
344 different magnitude) or sex-limited effects. For instance, Winkler et al. (2015) report 44 loci
345 with sex-specific or sex-limited effects but only 11 with sex-opposite effects. Several other
346 genome-wide association studies report sex-specific effects in several human diseases
347 (Khramtsova et al., 2019), and a recent (non-systematic) review identified 37 SNPs with sex-
348 dependent effects (Gilks et al., 2014). Detection of loci with SA versus sex-specific or sex-
349 limited effects may differ systematically since we expect SA loci are more likely to persist at
350 intermediate frequencies than loci with sex-specific effects (i.e. that differ between the sexes
351 in magnitude but not sign). A larger systematic review that targeted variants with sex-specific
352 or sex-dependent effects would therefore be a valuable contribution and enable us to more
353 clearly understand how important SA alleles are relative to the broader context of genes with
354 non-identical effects in the two sexes.

355 A key gap in our knowledge is whether the putative examples of sex-opposite or SA
356 alleles presented here can be validated using independently derived datasets in the same or
357 different sub-populations. For this, focussing on those variants associated with sex-
358 differential disease risk would naturally be the most fruitful for advancing our knowledge of
359 sexual antagonism in human disease. We therefore encourage specialists for the particular
360 disease groups presented in Table 1 to include in the future the potential for SA genetic
361 effects to occur when designing studies and analysing data. It is also important for all studies
362 to report results in sufficient detail so that effect sizes can be calculated (if not given) as well
363 as allele frequency data. Unfortunately, 17 studies failed to do this, so could not be included
364 in our review and subsequent test of the evolutionary model. More generally, our study
365 reinforces the view that sex is an important factor in shaping genetic associations with human

traits and disease, even in divergent and contradictory ways, and so should always be considered when investigators examine genetic associations with phenotypes (Lee, 2018; Ober et al., 2008).

There is a possibility that some bias exists in the PubMed database against papers from the field of evolutionary biology, and if we had used another database then both stages would have returned valid papers. We subsequently (14th Dec 2020) sought to investigate this possibility with additional searches of Scopus and Web of Science. Repeating the Stage 1 search initially returned 85 papers in Web of Science (Basic search of Topic, refined by "Human" within results) and 71 papers in Scopus (include keywords "Human", exclude "Non-Human"), but again no papers made it through the screening process. Repeating the Stage 2 search returned a much larger number of studies in both Web of Science (4,573; Basic search of Topic, refined by "Human" within results) and Scopus (6,616; Advanced search of Title-Abstract, filter: include human and humans, exclude nonhumans, Articles only), with 8,604 unique records. This large number of records is too many to currently screen and may harbour further examples of SA loci in humans, but it is noteworthy that the majority of the initial list of studies found during Stage 2 using PubMed were also found in the other two databases (712 out of 881) as well as 28 out of the screened list of 32 studies identified in the current systematic review.

The disparity between the two stages of the review process provides a remarkable example of how discipline-specific terminology and concepts can hinder scientific communication between fields for substantial periods of time. For many of the studies identified in this review, the focus of the research was not on quantifying or even identifying sex-specific genetic effects in traits or disease, although they were tested for. The responses to such findings varied. Some framed these results as a major finding, others merely made note of them, with one suggesting that since the genetic associations were in opposite directions in the two sexes then it should be regarded as a false positive (Wong et al., 2005). It is possible, or even likely then that there exists a publication bias in the biomedical sciences against studies with apparently incongruous sex-opposite or SA effects, perhaps in part because the evolutionary framework that may provide a context for understanding those results is not generally appreciated or known. Of course, for evolutionary biologists interested in the role of SA selection on human traits and disease, this is clearly a problem. For many years no specific examples of SA loci were known in humans, and yet the first putative

examples in fact appeared in the literature two decades ago. Our systematic review therefore provides a concrete illustration of how advances to both fields have likely been hampered by a limited understanding of the theoretical framework and terminology used by the neighbouring field.

How can communication between the fields of medicine and evolutionary biology be facilitated? We do not have a comprehensive answer but clearly training in, or an increased awareness of, evolutionary medicine for scientists in both camps would probably be beneficial. The topic of evolutionary biology now forms a key part of the education for some biomedical scientists and clinicians. Similarly, evolutionary medicine is now frequently included in fundamental textbooks on evolution, and is being taught to students of evolutionary biology as part of their degree courses. These changes have been relatively recent, are far from being universally employed, but they should be encouraged. Funders of primary research are also now actively encouraging or obliging researchers to include sex as a factor when designing their studies (Clayton and Collins, 2014), although this may simply result in studies that aim to control for rather than investigate these effects explicitly. Consequently even this remedy may still preclude a deeper understanding of the origins of some human diseases.

Acknowledgements

We thank Jessica Abbott, Tim Connallon and Filip Ruzicka for comments on a previous version of the MS. Funding was provided by the Swedish Research Council (Grant number: 2019-03567) and by the Royal Society to EHM as a University Research Fellowship and Enhancement Award. TJ was funded by the Centre national de la recherche scientifique (CNRS) and the German Research Foundation (DFG grant number: JA 2653/2-1).

Competing Interest Statement

The authors have declared no competing interest.

426 ## References

427 Albers, P.K., McVean, G., 2018. Dating genomic variants and shared ancestry in population-
428 scale sequencing data (preprint). Genomics. https://doi.org/10.1101/416610
429 Auton, A., Abecasis, G.R., Altshuler, D.M., Durbin, R.M., Abecasis, G.R., Bentley, D.R.,
430 Chakravarti, A., Clark, A.G., Donnelly, P., Eichler, E.E., Flicek, P., Gabriel, S.B., Gibbs,
431 R.A., Green, E.D., Hurles, M.E., Knoppers, B.M., Korbel, J.O., Lander, E.S., Lee, C.,
432 Lehrach, H., Mardis, E.R., Marth, G.T., McVean, G.A., Nickerson, D.A., Schmidt, J.P.,
433 Sherry, S.T., Wang, J., Wilson, R.K., Gibbs, R.A., Boerwinkle, E., Doddapaneni, H., Han,
434 Y., Korchina, V., Kovar, C., Lee, S., Muzny, D., Reid, J.G., Zhu, Y., Wang, J., Chang, Y.,
435 Feng, Q., Fang, X., Guo, X., Jian, M., Jiang, H., Jin, X., Lan, T., Li, G., Li, J., Li, Y., Liu, S.,
436 Liu, X., Lu, Y., Ma, X., Tang, M., Wang, B., Wang, G., Wu, H., Wu, R., Xu, X., Yin, Y.,
437 Zhang, D., Zhang, W., Zhao, J., Zhao, M., Zheng, X., Lander, E.S., Altshuler, D.M.,
438 Gabriel, S.B., Gupta, N., Gharani, N., Toji, L.H., Gerry, N.P., Resch, A.M., Flicek, P.,
439 Barker, J., Clarke, L., Gil, L., Hunt, S.E., Kelman, G., Kulesha, E., Leinonen, R., McLaren,
440 W.M., Radhakrishnan, R., Roa, A., Smirnov, D., Smith, R.E., Streeter, I., Thormann, A.,
441 Toneva, I., Vaughan, B., Zheng-Bradley, X., Bentley, D.R., Grocock, R., Humphray, S.,
442 James, T., Kingsbury, Z., Lehrach, H., Sudbrak, R., Albrecht, M.W., Amstislavskiy, V.S.,
443 Borodina, T.A., Lienhard, M., Mertes, F., Sultan, M., Timmermann, B., Yaspo, M.-L.,
444 Mardis, E.R., Wilson, R.K., Fulton, L., Fulton, R., Sherry, S.T., Ananiev, V., Belaia, Z.,
445 Beloslyudtsev, D., Bouk, N., Chen, C., Church, D., Cohen, R., Cook, C., Garner, J.,
446 Hefferon, T., Kimelman, M., Liu, C., Lopez, J., Meric, P., O'Sullivan, C., Ostapchuk, Y.,
447 Phan, L., Ponomarov, S., Schneider, V., Shekhtman, E., Sirotkin, K., Slotta, D., Zhang,
448 H., McVean, G.A., Durbin, R.M., Balasubramaniam, S., Burton, J., Danecek, P., Keane,
449 T.M., Kolb-Kokocinski, A., McCarthy, S., Stalker, J., Quail, M., Schmidt, J.P., Davies,
450 C.J., Gollub, J., Webster, T., Wong, B., Zhan, Y., Auton, A., Campbell, C.L., Kong, Y.,
451 Marcketta, A., Gibbs, R.A., Yu, F., Antunes, L., Bainbridge, M., Muzny, D., Sabo, A.,
452 Huang, Z., Wang, J., Coin, L.J.M., Fang, L., Guo, X., Jin, X., Li, G., Li, Q., Li, Y., Li, Z., Lin,
453 H., Liu, B., Luo, R., Shao, H., Xie, Y., Ye, C., Yu, C., Zhang, F., Zheng, H., Zhu, H., Alkan,
454 C., Dal, E., Kahveci, F., Marth, G.T., Garrison, E.P., Kural, D., Lee, W.-P., Fung Leong,
455 W., Stromberg, M., Ward, A.N., Wu, J., Zhang, M., Daly, M.J., DePristo, M.A.,
456 Handsaker, R.E., Altshuler, D.M., Banks, E., Bhatia, G., del Angel, G., Gabriel, S.B.,
457 Genovese, G., Gupta, N., Li, H., Kashin, S., Lander, E.S., McCarroll, S.A., Nemesh, J.C.,
458 Poplin, R.E., Yoon, S.C., Lihm, J., Makarov, V., Clark, A.G., Gottipati, S., Keinan, A.,
459 Rodriguez-Flores, J.L., Korbel, J.O., Rausch, T., Fritz, M.H., Stütz, A.M., Flicek, P., Beal,
460 K., Clarke, L., Datta, A., Herrero, J., McLaren, W.M., Ritchie, G.R.S., Smith, R.E.,
461 Zerbino, D., Zheng-Bradley, X., Sabeti, P.C., Shlyakhter, I., Schaffner, S.F., Vitti, J.,
462 Cooper, D.N., Ball, E.V., Stenson, P.D., Bentley, D.R., Barnes, B., Bauer, M., Keira
463 Cheetham, R., Cox, A., Eberle, M., Humphray, S., Kahn, S., Murray, L., Peden, J.,
464 Shaw, R., Kenny, E.E., Batzer, M.A., Konkel, M.K., Walker, J.A., MacArthur, D.G., Lek,
465 M., Sudbrak, R., Amstislavskiy, V.S., Herwig, R., Mardis, E.R., Ding, L., Koboldt, D.C.,
466 Larson, D., Ye, K., Gravel, S., The 1000 Genomes Project Consortium, Corresponding
467 authors, Steering committee, Production group, Baylor College of Medicine, BGI-
468 Shenzhen, Broad Institute of MIT and Harvard, Coriell Institute for Medical Research,
469 European Molecular Biology Laboratory, E.B.I., Illumina, Max Planck Institute for
470 Molecular Genetics, McDonnell Genome Institute at Washington University, US
471 National Institutes of Health, University of Oxford, Wellcome Trust Sanger Institute,

472 Analysis group, Affymetrix, Albert Einstein College of Medicine, Bilkent University,
473 Boston College, Cold Spring Harbor Laboratory, Cornell University, European
474 Molecular Biology Laboratory, Harvard University, Human Gene Mutation Database,
475 Icahn School of Medicine at Mount Sinai, Louisiana State University, Massachusetts
476 General Hospital, McGill University, National Eye Institute, N., 2015. A global
477 reference for human genetic variation. Nature 526, 68–74.
478 https://doi.org/10.1038/nature15393
479 Barson, N.J., Aykanat, T., Hindar, K., Baranski, M., Bolstad, G.H., Fiske, P., Jacq, C., Jensen,
480 A.J., Johnston, S.E., Karlsson, S., Kent, M., Moen, T., Niemelä, E., Nome, T., Næsje,
481 T.F., Orell, P., Romakkaniemi, A., Sægrov, H., Urdal, K., Erkinaro, J., Lien, S., Primmer,
482 C.R., 2015. Sex-dependent dominance at a single locus maintains variation in age at
483 maturity in salmon. Nature 528, 405–408. https://doi.org/10.1038/nature16062
484 Bonduriansky, R., Chenoweth, S.F., 2009. Intralocus sexual conflict. Trends Ecol Evol 24,
485 280–288.
486 Borenstein, M., 2009. Converting Among Effect Sizes, in: Introduction to Meta-Analysis. John
487 Wiley & Sons, Ltd, pp. 45–49. https://doi.org/10.1002/9780470743386.ch7
488 Camus, M.F., Wolf, J.B.W., Morrow, E.H., Dowling, D.K., 2015. Single Nucleotides in the
489 mtDNA Sequence Modify Mitochondrial Molecular Function and Are Associated with
490 Sex-Specific Effects on Fertility and Aging. Curr. Biol. 25, 2717–2722.
491 https://doi.org/10.1016/j.cub.2015.09.012
492 Carlson, J.C., Nidey, N.L., Butali, A., Buxo, C.J., Christensen, K., Deleyiannis, F.W.-D., Hecht,
493 J.T., Field, L.L., Moreno-Uribe, L.M., Orioli, I.M., Poletta, F.A., Padilla, C., Vieira, A.R.,
494 Weinberg, S.M., Wehby, G.L., Feingold, E., Murray, J.C., Marazita, M.L., Leslie, E.J.,
495 2018. Genome-wide interaction studies identify sex-specific risk alleles for
496 nonsyndromic orofacial clefts. Genet. Epidemiol. 42, 664–672.
497 https://doi.org/10.1002/gepi.22158
498 Chippindale, A.K., Gibson, J.R., Rice, W.R., 2001. Negative genetic correlation for adult
499 fitness between sexes reveals ontogenetic conflict in Drosophila. Proc. Natl. Acad.
500 Sci. USA 98, 1671–1675.
501 Cicchetti, D., Rogosch, F.A., Hecht, K.F., Crick, N.R., Hetzel, S., 2014. Moderation of
502 maltreatment effects on childhood borderline personality symptoms by gender and
503 oxytocin receptor and FK506 binding protein 5 genes. Dev. Psychopathol. 26, 831–
504 849. https://doi.org/10.1017/S095457941400042X
505 Clayton, J.A., Collins, F.S., 2014. Policy: NIH to balance sex in cell and animal studies. Nature
506 509, 282–283. https://doi.org/10.1038/509282a
507 Connallon, T., Clark, A., G., 2014. Evolutionary inevitability of sexual antagonism. Proc. R.
508 Soc. B Biol. Sci. 281, 20132123. https://doi.org/10.1098/rspb.2013.2123
509 Connallon, T., Clark, A.G., 2013. Antagonistic Versus Nonantagonistic Models of Balancing
510 Selection: Characterizing the Relative Timescales and Hitchhiking Effects of Partial
511 Selective Sweeps. Evolution 67, 908–917. https://doi.org/10.1111/j.1558-
512 5646.2012.01800.x
513 Dauvilliers, Y., Neidhart, E., Lecendreux, M., Billiard, M., Tafti, M., 2001. MAO-A and COMT
514 polymorphisms and gene effects in narcolepsy. Mol. Psychiatry 6, 367–372.
515 https://doi.org/10.1038/sj.mp.4000911
516 Dixson, A., 2009. Dixson, A. F. (2009) Sexual selection and the Origins of Human Mating
517 Systems. Oxford University Press, UK.

518 Ellegren, H., Parsch, J., 2007. The evolution of sex-biased genes and sex-biased gene
519 expression. Nat Rev Genet 8, 689–698. https://doi.org/10.1038/nrg2167
520 Fillingim, R.B., Kaplan, L., Staud, R., Ness, T.J., Glover, T.L., Campbell, C.M., Mogil, J.S.,
521 Wallace, M.R., 2005. The A118G single nucleotide polymorphism of the mu-opioid
522 receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J. Pain
523 Off. J. Am. Pain Soc. 6, 159–167. https://doi.org/10.1016/j.jpain.2004.11.008
524 Fitzpatrick, M.J., 2004. Pleiotropy and the genomic location of sexually selected genes. Am.
525 Nat. 163, 800–808. https://doi.org/10.1086/386297
526 Foerster, K., Coulson, T., Sheldon, B.C., Pemberton, J.M., Clutton-Brock, T., Kruuk, L.E.B.,
527 2007. Sexually antagonistic genetic variation for fitness in red deer. Nature 447,
528 1107–1110.
529 Franck, N., Lanne, T., Astrand, O., Engvall, J., Lindstrom, T., Ostgren, C.J., Nystrom, F.H.,
530 2012. Cardiovascular risk factors related to the PPARgamma Pro12Ala polymorphism
531 in patients with type 2 diabetes are gender dependent. Blood Press. 21, 122–127.
532 https://doi.org/10.3109/08037051.2011.623349
533 Fry, J.D., 2010. The Genomic Location of Sexually Antagonistic Variation: Some Cautionary
534 Comments. Evolution 64, 1510–1516. https://doi.org/10.1111/j.1558-
535 5646.2009.00898.x
536 Garver-Apgar, C.E., Eaton, M.A., Tybur, J.M., Emery Thompson, M., 2011. Evidence of
537 intralocus sexual conflict: physically and hormonally masculine individuals have more
538 attractive brothers relative to sisters. Evol. Hum. Behav. 32, 423–432.
539 https://doi.org/10.1016/j.evolhumbehav.2011.03.005
540 Gastaldi, M., Diziere, S., Defoort, C., Portugal, H., Lairon, D., Darmon, M., Planells, R., 2007.
541 Sex-specific association of fatty acid binding protein 2 and microsomal triacylglycerol
542 transfer protein variants with response to dietary lipid changes in the 3-mo Medi-
543 RIVAGE primary intervention study. Am. J. Clin. Nutr. 86, 1633–1641.
544 https://doi.org/10.1093/ajcn/86.5.1633
545 Gilks, W.P., Abbott, J.K., Morrow, E.H., 2014. Sex differences in disease genetics: evidence,
546 evolution, and detection. Trends Genet. 30, 453–463.
547 https://doi.org/10.1016/j.tig.2014.08.006
548 Gloria-Bottini, F., Bottini, N., Renzetti, G., Bottini, E., 2007. ACP1 and Th class of
549 immunological disease: evidence of interaction with gender. Int. Arch. Allergy
550 Immunol. 143, 170–176. https://doi.org/10.1159/000099308
551 Grieshop, K., Arnqvist, G., 2018. Sex-specific dominance reversal of genetic variation for
552 fitness. PLOS Biol. 16, e2006810. https://doi.org/10.1371/journal.pbio.2006810
553 Gurevitch, J., Koricheva, J., Mengersen, K., 2013. Handbook of Meta-Analysis In Ecology and
554 Evolution, Handbook of Meta-analysis in Ecology and Evolution.
555 https://doi.org/10.1515/9781400846184
556 Herman, A.I., Conner, T.S., Anton, R.F., Gelernter, J., Kranzler, H.R., Covault, J., 2011.
557 Variation in the gene encoding the serotonin transporter is associated with a
558 measure of sociopathy in alcoholics. Addict. Biol. 16, 124–132.
559 https://doi.org/10.1111/j.1369-1600.2009.00197.x
560 Khramtsova, E.A., Davis, L.K., Stranger, B.E., 2019. The role of sex in the genomics of human
561 complex traits. Nat. Rev. Genet. 20, 173–190. https://doi.org/10.1038/s41576-018-
562 0083-1

563 Kim, B., Kim, H., Joo, Y.H., Lim, J., Kim, C.-Y., Song, K., 2010. Sex-different association of DAO
564 with schizophrenia in Koreans. Psychiatry Res. 179, 121–125.
565 https://doi.org/10.1016/j.psychres.2008.08.009
566 Kiy, A., Wilhelm, O., Hildebrandt, A., Reuter, M., Sommer, W., 2013. On the genetic basis of
567 face cognition and its relation to fluid cognitive abilities. Genes Brain Behav. 12, 438–
568 445. https://doi.org/10.1111/gbb.12034
569 Korner, A., Ma, L., Franks, P.W., Kiess, W., Baier, L.J., Stumvoll, M., Kovacs, P., 2007. Sex-
570 specific effect of the Val1483Ile polymorphism in the fatty acid synthase gene (FAS)
571 on body mass index and lipid profile in Caucasian children. Int. J. Obes. 2005 31,
572 353–358. https://doi.org/10.1038/sj.ijo.0803428
573 Lajeunesse, M., 2013. Recovering missing or partial data from studies: A survey of
574 conversions and imputations for meta-analysis. pp. 195–206.
575 Lande, R., 1980. Sexual dimorphism, sexual selection, and adaptation in polygenic
576 characters. Evolution 34, 292–305.
577 Lang, U.E., Hellweg, R., Bajbouj, M., Gaus, V., Sander, T., Gallinat, J., 2008. Gender-
578 dependent association of a functional NGF polymorphism with anxiety-related
579 personality traits. Pharmacopsychiatry 41, 196–199. https://doi.org/10.1055/s-0028-
580 1082070
581 Lauritzen, L., Sorensen, L.B., Harslof, L.B., Ritz, C., Stark, K.D., Astrup, A., Dyssegaard, C.B.,
582 Egelund, N., Michaelsen, K.F., Damsgaard, C.T., 2017. Mendelian randomization
583 shows sex-specific associations between long-chain. Am. J. Clin. Nutr. 106, 88–95.
584 https://doi.org/10.3945/ajcn.117.152595
585 Lee, S.K., 2018. Sex as an important biological variable in biomedical research. BMB Rep. 51,
586 167–173. https://doi.org/10.5483/BMBRep.2018.51.4.034
587 Liu, Y.-H., Chen, Y.-J., Wu, H.-H., Wang, T.-Y., Tsai, F.-J., 2014. Single nucleotide
588 polymorphisms at the PRR3, ABCF1, and GNL1 genes in the HLA class I region are
589 associated with Graves' ophthalmopathy in a gender-dependent manner.
590 Ophthalmology 121, 2033–2039. https://doi.org/10.1016/j.ophtha.2014.04.027
591 Ljungberg, L.U., Ostgren, C.J., Nystrom, F.H., Lanne, T., 2014. Associations of genetic
592 polymorphisms in the renin-angiotensin system with central aortic and ambulatory
593 blood pressure in type 2 diabetic patients. J. Renin-Angiotensin-Aldosterone Syst.
594 JRAAS 15, 61–68. https://doi.org/10.1177/1470320312474052
595 McCarthy, J.J., Somji, A., Weiss, L.A., Steffy, B., Vega, R., Barrett-Connor, E., Talavera, G.,
596 Glynne, R., 2009. Polymorphisms of the scavenger receptor class B member 1 are
597 associated with insulin resistance with evidence of gene by sex interaction. J. Clin.
598 Endocrinol. Metab. 94, 1789–1796. https://doi.org/10.1210/jc.2008-2800
599 Mills, S.C., Koskela, E., Mappes, T., 2011. Intralocus sexual conflict for fitness: sexually
600 antagonistic alleles for testosterone. Proc. R. Soc. B Biol. Sci. rspb20112340.
601 https://doi.org/10.1098/rspb.2011.2340
602 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, T.P., 2009. Preferred Reporting
603 Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS
604 Med. 6, e1000097. https://doi.org/10.1371/journal.pmed.1000097
605 Morea, A., Cameran, M., Rebuffi, A.G., Marzenta, D., Marangon, O., Picci, L., Zacchello, F.,
606 Scarpa, M., 2005. Gender-sensitive association of CFTR gene mutations and 5T allele
607 emerging from a large survey on infertility. Mol. Hum. Reprod. 11, 607–614.
608 https://doi.org/10.1093/molehr/gah214

Morrow, E.H., 2015. The evolution of sex differences in disease. Biol. Sex Differ. 6, 5. https://doi.org/10.1186/s13293-015-0023-0

Morrow, E.H., Connallon, T., 2013. Implications of sex-specific selection for the genetic basis of disease. Evol. Appl. 6, 1208–1217. https://doi.org/10.1111/eva.12097

Nesse, R.M., Williams, G.C., 1994. Why we get sick: The new science of Darwinian medicine. Vintage, New York.

Ober, C., Loisel, D.A., Gilad, Y., 2008. Sex-specific genetic architecture of human disease. Nat Rev Genet 9, 911–922. https://doi.org/10.1038/nrg2415

Ober, C., Pan, L., Phillips, N., Parry, R., Kurina, L.M., 2006. Sex-specific genetic architecture of asthma-associated quantitative trait loci in a founder population. Curr. Allergy Asthma Rep. 6, 241–246. https://doi.org/10.1007/s11882-006-0041-4

Ovadia, G., Shifman, S., 2011. The genetic variation of RELN expression in schizophrenia and bipolar disorder. PloS One 6, e19955. https://doi.org/10.1371/journal.pone.0019955

Padmanabhan, S., Menni, C., Lee, W.K., Laing, S., Brambilla, P., Sega, R., Perego, R., Grassi, G., Cesana, G., Delles, C., Mancia, G., Dominiczak, A.F., 2010. The effects of sex and method of blood pressure measurement on genetic associations with blood pressure in the PAMELA study. J. Hypertens. 28, 465–477. https://doi.org/10.1097/HJH.0b013e32833594d7

Parker, G.A., 1979. SEXUAL SELECTION AND SEXUAL CONFLICT, in: Sexual Selection and Reproductive Competition in Insects. Elsevier, pp. 123–166. https://doi.org/10.1016/B978-0-12-108750-0.50010-0

Parker, G.A., Baker, R.R., Smith, V.G.F., 1972. The origin and evolution of gamete dimorphism and the male-female phenomenon. J. Theor. Biol. 36, 529–553.

Payne, E.H., Gebregziabher, M., Hardin, J.W., Ramakrishnan, V., Egede, L.E., 2018. An empirical approach to determine a threshold for assessing overdispersion in Poisson and negative binomial models for count data. Commun. Stat. Simul. Comput. 47, 1722–1738. https://doi.org/10.1080/03610918.2017.1323223

Peng, Y.-M., Lei, S.-F., Guo, Y., Xiong, D.-H., Yan, H., Wang, L., Guo, Y.-F., Deng, H.-W., 2008. Sex-specific association of the glucocorticoid receptor gene with extreme BMD. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 23, 247–252. https://doi.org/10.1359/jbmr.071017

Pennell, T.M., Haas, F.J.H. de, Morrow, E.H., Doorn, G.S. van, 2016. Contrasting effects of intralocus sexual conflict on sexually antagonistic coevolution. Proc. Natl. Acad. Sci. 113, E978–E986. https://doi.org/10.1073/pnas.1514328113

Pennell, T.M., Morrow, E.H., 2013. Two sexes, one genome: the evolutionary dynamics of intralocus sexual conflict. Ecol. Evol. 3, 1819–1834. https://doi.org/10.1002/ece3.540

Press, O.A., Zhang, W., Gordon, M.A., Yang, D., Haiman, C.A., Azuma, M., Iqbal, S., Lenz, H.-J., 2011. Gender-related survival differences associated with polymorphic variants of estrogen receptor-beta (ERbeta) in patients with metastatic colon cancer. Pharmacogenomics J. 11, 375–382. https://doi.org/10.1038/tpj.2010.45

Price, J.S., Strong, J., Eliassen, J., McQueeny, T., Miller, M., Padula, C.B., Shear, P., Lisdahl, K., 2013. Serotonin transporter gene moderates associations between mood, memory and hippocampal volume. Behav. Brain Res. 242, 158–165. https://doi.org/10.1016/j.bbr.2012.11.013

Rice, W.R., 1992. Sexually antagonistic genes: experimental evidence. Science 256, 1436–1439. https://doi.org/10.1126/science.1604317

656 Rice, W.R., 1984. Sex chromosomes and the evolution of sexual dimorphism. Evolution 38,
657 735–742.
658 Rigby, N., Kulathinal, R.J., 2015. Genetic Architecture of Sexual Dimorphism in Humans. J.
659 Cell. Physiol. 230, 2304–2310. https://doi.org/10.1002/jcp.24979
660 Rostant, W.G., Kay, C., Wedell, N., Hosken, D.J., 2015. Sexual conflict maintains variation at
661 an insecticide resistance locus. BMC Biol. 13. https://doi.org/10.1186/s12915-015-
662 0143-3
663 Ruzicka, F., Connallon, T., 2020. Is the X chromosome a hot spot for sexually antagonistic
664 polymorphisms? Biases in current empirical tests of classical theory. Proc. R. Soc. B.
665 https://doi.org/10.1098/rspb.2020.1869
666 Ruzicka, F., Dutoit, L., Czuppon, P., Jordan, C.Y., Li, X.-Y., Olito, C., Runemark, A., Svensson,
667 E.I., Yazdi, H.P., Connallon, T., 2020. The search for sexually antagonistic genes:
668 Practical insights from studies of local adaptation and statistical genomics. Evol. Lett.
669 4–5, 398–415. https://doi.org/10.1002/evl3.192
670 Ruzicka, F., Hill, M.S., Pennell, T.M., Flis, I., Ingleby, F.C., Mott, R., Fowler, K., Morrow, E.H.,
671 Reuter, M., 2019. Genome-wide sexually antagonistic variants reveal long-standing
672 constraints on sexual dimorphism in fruit flies. PLoS Biol. 17, e3000244.
673 Sainz, J., Rudolph, A., Hoffmeister, M., Frank, B., Brenner, H., Chang-Claude, J., Hemminki,
674 K., Forsti, A., 2012. Effect of type 2 diabetes predisposing genetic variants on
675 colorectal cancer risk. J. Clin. Endocrinol. Metab. 97, E845-851.
676 https://doi.org/10.1210/jc.2011-2565
677 Sangalli, A., Orlandi, E., Poli, A., Maurichi, A., Santinami, M., Nicolis, M., Ferronato, S.,
678 Malerba, G., Rodolfo, M., Gomez Lira, M., 2017. Sex-specific effect of RNASEL
679 rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility
680 factor for melanoma skin cancer. Melanoma Res. 27, 309–314.
681 https://doi.org/10.1097/CMR.0000000000000360
682 Schneider, K.K., Hule, L., Schote, A.B., Meyer, J., Frings, C., 2015. Sex matters! Interactions of
683 sex and polymorphisms of a cholinergic receptor gene (CHRNA5) modulate response
684 speed. Neuroreport 26, 186–191. https://doi.org/10.1097/WNR.0000000000000313
685 Schuurhof, A., Bont, L., Siezen, C.L.E., Hodemaekers, H., van Houwelingen, H.C., Kimman,
686 T.G., Hoebee, B., Kimpen, J.L.L., Janssen, R., 2010. Interleukin-9 polymorphism in
687 infants with respiratory syncytial virus infection: an opposite effect in boys and girls.
688 Pediatr. Pulmonol. 45, 608–613. https://doi.org/10.1002/ppul.21229
689 Shalev, I., Lerer, E., Israel, S., Uzefovsky, F., Gritsenko, I., Mankuta, D., Ebstein, R.P., Kaitz,
690 M., 2009. BDNF Val66Met polymorphism is associated with HPA axis reactivity to
691 psychological stress characterized by genotype and gender interactions.
692 Psychoneuroendocrinology 34, 382–388.
693 https://doi.org/10.1016/j.psyneuen.2008.09.017
694 Short, R.V., 1979. Sexual selection and its component parts, somatic and genital selection, as
695 illustrated by man and the great apes. Adv. Study Behav. 9, 131–158.
696 Sjoberg, R.L., Nilsson, K.W., Nordquist, N., Ohrvik, J., Leppert, J., Lindstrom, L., Oreland, L.,
697 2006. Development of depression: sex and the interaction between environment
698 and a promoter polymorphism of the serotonin transporter gene. Int. J.
699 Neuropsychopharmacol. 9, 443–449. https://doi.org/10.1017/S1461145705005936
700 Stearns, S.C., Govindaraju, D.R., Ewbank, D., Byars, S.G., 2012. Constraints on the
701 coevolution of contemporary human males and females. Proc. R. Soc. B Biol. Sci. 279,
702 4836–4844. https://doi.org/10.1098/rspb.2012.2024

Stulp, G., Kuijper, B., Buunk, A.P., Pollet, T.V., Verhulst, S., 2012. Intralocus sexual conflict over human height. Biol. Lett. https://doi.org/10.1098/rsbl.2012.0590

Winkler, T.W., Justice, A.E., Graff, M., Barata, L., Feitosa, M.F., Chu, S., Czajkowski, J., Esko, T., Fall, T., Kilpeläinen, T.O., Lu, Y., Mägi, R., Mihailov, E., Pers, T.H., Rüeger, S., Teumer, A., Ehret, G.B., Ferreira, T., Heard-Costa, N.L., Karjalainen, J., Lagou, V., Mahajan, A., Neinast, M.D., Prokopenko, I., Simino, J., Teslovich, T.M., Jansen, R., Westra, H.-J., White, C.C., Absher, D., Ahluwalia, T.S., Ahmad, S., Albrecht, E., Alves, A.C., Bragg-Gresham, J.L., Craen, A.J.M. de, Bis, J.C., Bonnefond, A., Boucher, G., Cadby, G., Cheng, Y.-C., Chiang, C.W.K., Delgado, G., Demirkan, A., Dueker, N., Eklund, N., Eiriksdottir, G., Eriksson, J., Feenstra, B., Fischer, K., Frau, F., Galesloot, T.E., Geller, F., Goel, A., Gorski, M., Grammer, T.B., Gustafsson, S., Haitjema, S., Hottenga, J.-J., Huffman, J.E., Jackson, A.U., Jacobs, K.B., Johansson, Å., Kaakinen, M., Kleber, M.E., Lahti, J., Leach, I.M., Lehne, B., Liu, Y., Lo, K.S., Lorentzon, M., Luan, J., Madden, P.A.F., Mangino, M., McKnight, B., Medina-Gomez, C., Monda, K.L., Montasser, M.E., Müller, G., Müller-Nurasyid, M., Nolte, I.M., Panoutsopoulou, K., Pascoe, L., Paternoster, L., Rayner, N.W., Renström, F., Rizzi, F., Rose, L.M., Ryan, K.A., Salo, P., Sanna, S., Scharnagl, H., Shi, J., Smith, A.V., Southam, L., Stančáková, A., Steinthorsdottir, V., Strawbridge, R.J., Sung, Y.J., Tachmazidou, I., Tanaka, T., Thorleifsson, G., Trompet, S., Pervjakova, N., Tyrer, J.P., Vandenput, L., Laan, S.W. van der, Velde, N. van der, Setten, J. van, Vliet-Ostaptchouk, J.V. van, Verweij, N., Vlachopoulou, E., Waite, L.L., Wang, S.R., Wang, Z., Wild, S.H., Willenborg, C., Wilson, J.F., Wong, A., Yang, J., Yengo, L., Yerges-Armstrong, L.M., Yu, L., Zhang, W., Zhao, J.H., Andersson, E.A., Bakker, S.J.L., Baldassarre, D., Banasik, K., Barcella, M., Barlassina, C., Bellis, C., Benaglio, P., Blangero, J., Blüher, M., Bonnet, F., Bonnycastle, L.L., Boyd, H.A., Bruinenberg, M., Buchman, A.S., Campbell, H., Chen, Y.-D.I., Chines, P.S., Claudi-Boehm, S., Cole, J., Collins, F.S., Geus, E.J.C. de, Groot, L.C.P.G.M. de, Dimitriou, M., Duan, J., Enroth, S., Eury, E., Farmaki, A.-E., Forouhi, N.G., Friedrich, N., Gejman, P.V., Gigante, B., Glorioso, N., Go, A.S., Gottesman, O., Gräßler, J., Grallert, H., Grarup, N., Gu, Y.-M., Broer, L., Ham, A.C., Hansen, T., Harris, T.B., Hartman, C.A., Hassinen, M., Hastie, N., Hattersley, A.T., Heath, A.C., Henders, A.K., Hernandez, D., Hillege, H., Holmen, O., Hovingh, K.G., Hui, J., Husemoen, L.L., Hutri-Kähönen, N., Hysi, P.G., Illig, T., Jager, P.L.D., Jalilzadeh, S., Jørgensen, T., Jukema, J.W., Juonala, M., Kanoni, S., Karaleftheri, M., Khaw, K.T., Kinnunen, L., Kittner, S.J., Koenig, W., Kolcic, I., Kovacs, P., Krarup, N.T., Kratzer, W., Krüger, J., Kuh, D., Kumari, M., Kyriakou, T., Langenberg, C., Lannfelt, L., Lanzani, C., Lotay, V., Launer, L.J., Leander, K., Lindström, J., Linneberg, A., Liu, Y.-P., Lobbens, S., Luben, R., Lyssenko, V., Männistö, S., Magnusson, P.K., McArdle, W.L., Menni, C., Merger, S., Milani, L., Montgomery, G.W., Morris, A.P., Narisu, N., Nelis, M., Ong, K.K., Palotie, A., Pérusse, L., Pichler, I., Pilia, M.G., Pouta, A., Rheinberger, M., Ribel-Madsen, R., Richards, M., Rice, K.M., Rice, T.K., Rivolta, C., Salomaa, V., Sanders, A.R., Sarzynski, M.A., Scholtens, S., Scott, R.A., Scott, W.R., Sebert, S., Sengupta, S., Sennblad, B., Seufferlein, T., Silveira, A., Slagboom, P.E., Smit, J.H., Sparsø, T.H., Stirrups, K., Stolk, R.P., Stringham, H.M., Swertz, M.A., Swift, A.J., Syvänen, A.-C., Tan, S.-T., Thorand, B., Tönjes, A., Tremblay, A., Tsafantakis, E., Most, P.J. van der, Völker, U., Vohl, M.-C., Vonk, J.M., Waldenberger, M., Walker, R.W., Wennauer, R., Widén, E., Willemsen, G., Wilsgaard, T., Wright, A.F., Zillikens, M.C., Dijk, S.C. van, Schoor, N.M. van, Asselbergs, F.W., Bakker, P.I.W. de, Beckmann, J.S., Beilby, J., Bennett, D.A.,

Bergman, R.N., Bergmann, S., Böger, C.A., Boehm, B.O., Boerwinkle, E., Boomsma, D.I., Bornstein, S.R., Bottinger, E.P., Bouchard, C., Chambers, J.C., Chanock, S.J., Chasman, D.I., Cucca, F., Cusi, D., Dedoussis, G., Erdmann, J., Eriksson, J.G., Evans, D.A., Faire, U. de, Farrall, M., Ferrucci, L., Ford, I., Franke, L., Franks, P.W., Froguel, P., Gansevoort, R.T., Gieger, C., Grönberg, H., Gudnason, V., Gyllensten, U., Hall, P., Hamsten, A., Harst, P. van der, Hayward, C., Heliövaara, M., Hengstenberg, C., Hicks, A.A., Hingorani, A., Hofman, A., Hu, F., Huikuri, H.V., Hveem, K., James, A.L., Jordan, J.M., Jula, A., Kähönen, M., Kajantie, E., Kathiresan, S., Kiemeney, L.A.L.M., Kivimaki, M., Knekt, P.B., Koistinen, H.A., Kooner, J.S., Koskinen, S., Kuusisto, J., Maerz, W., Martin, N.G., Laakso, M., Lakka, T.A., Lehtimäki, T., Lettre, G., Levinson, D.F., Lind, L., Lokki, M.-L., Mäntyselkä, P., Melbye, M., Metspalu, A., Mitchell, B.D., Moll, F.L., Murray, J.C., Musk, A.W., Nieminen, M.S., Njølstad, I., Ohlsson, C., Oldehinkel, A.J., Oostra, B.A., Palmer, L.J., Pankow, J.S., Pasterkamp, G., Pedersen, N.L., Pedersen, O., Penninx, B.W., Perola, M., Peters, A., Polašek, O., Pramstaller, P.P., Psaty, B.M., Qi, L., Quertermous, T., Raitakari, O.T., Rankinen, T., Rauramaa, R., Ridker, P.M., Rioux, J.D., Rivadeneira, F., Rotter, J.I., Rudan, I., Ruijter, H.M. den, Saltevo, J., Sattar, N., Schunkert, H., Schwarz, P.E.H., Shuldiner, A.R., Sinisalo, J., Snieder, H., Sørensen, T.I.A., Spector, T.D., Staessen, J.A., Stefania, B., Thorsteinsdottir, U., Stumvoll, M., Tardif, J.-C., Tremoli, E., Tuomilehto, J., Uitterlinden, A.G., Uusitupa, M., Verbeek, A.L.M., Vermeulen, S.H., Viikari, J.S., Vitart, V., Völzke, H., Vollenweider, P., Waeber, G., Walker, M., Wallaschofski, H., Wareham, N.J., Watkins, H., Zeggini, E., Consortium, C., Consortium, D., Consortium, G., Consortium, G.-Bpg., Consortium, I., Consortium, M., Chakravarti, A., Clegg, D.J., Cupples, L.A., Gordon-Larsen, P., Jaquish, C.E., Rao, D.C., Abecasis, G.R., Assimes, T.L., Barroso, I., Berndt, S.I., Boehnke, M., Deloukas, P., Fox, C.S., Groop, L.C., Hunter, D.J., Ingelsson, E., Kaplan, R.C., McCarthy, M.I., Mohlke, K.L., O'Connell, J.R., Schlessinger, D., Strachan, D.P., Stefansson, K., Duijn, C.M. van, Hirschhorn, J.N., Lindgren, C.M., Heid, I.M., North, K.E., Borecki, I.B., Kutalik, Z., Loos, R.J.F., 2015. The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. PLOS Genet. 11, e1005378. https://doi.org/10.1371/journal.pgen.1005378

Wise, A.L., Gyi, L., Manolio, T.A., 2013. eXclusion: Toward Integrating the X Chromosome in Genome-wide Association Analyses. Am. J. Hum. Genet. 92, 643–647. https://doi.org/10.1016/j.ajhg.2013.03.017

Wong, S.Y.S., Lau, E.M.C., Li, M., Chung, T., Sham, A., Woo, J., 2005. The prevalence of Apo E4 genotype and its relationship to bone mineral density in Hong Kong Chinese. J. Bone Miner. Metab. 23, 261–265. https://doi.org/10.1007/s00774-004-0593-0

Wu, K., Chen, C., Moyzis, R.K., Greenberger, E., Yu, Z., 2016. Gender Interacts with Opioid Receptor Polymorphism A118G and Serotonin Receptor Polymorphism -1438 A/G on Speed-Dating Success. Hum. Nat. Hawthorne N 27, 244–260. https://doi.org/10.1007/s12110-016-9257-8

Youssef, S.S., Abd El Aal, A.M., Nasr, A.S., el Zanaty, T., Seif, S.M., 2013. Interleukin-12B gene polymorphism frequencies in Egyptians and sex-related susceptibility to hepatitis C infection. J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res. 33, 415–419. https://doi.org/10.1089/jir.2012.0161

Supplementary Material

Both stages of the PubMed literature search employed a Species filter set to Humans only.

Stage 1 Search term:
((((((((((((((((((sexual antagonism[Title/Abstract] AND locus[Title/Abstract]) OR (sexual antagonism[Title/Abstract] AND loci[Title/Abstract])) OR (sexual antagonism[Title/Abstract] AND gene[Title/Abstract])) OR (sexual antagonism[Title/Abstract] AND snp[Title/Abstract])) OR (sexual antagonism[Title/Abstract] AND polymorphism[Title/Abstract])) OR (sexual antagonism[Title/Abstract] AND variant[Title/Abstract])) OR (sexual antagonism[Title/Abstract] AND allele[Title/Abstract])) OR (sexually antagonistic[Title/Abstract] AND locus[Title/Abstract])) OR (sexually antagonistic[Title/Abstract] AND loci[Title/Abstract])) OR (sexually antagonistic[Title/Abstract] AND gene[Title/Abstract])) OR (sexually antagonistic[Title/Abstract] AND snp[Title/Abstract])) OR (sexually antagonistic[Title/Abstract] AND polymorphism[Title/Abstract])) OR (sexually antagonistic[Title/Abstract] AND variant[Title/Abstract])) OR (sexually antagonistic[Title/Abstract] AND allele[Title/Abstract])) OR (intralocus sexual conflict[Title/Abstract] AND locus[Title/Abstract])) OR (intralocus sexual conflict[Title/Abstract] AND loci[Title/Abstract])) OR (intralocus sexual conflict[Title/Abstract] AND gene[Title/Abstract])) OR (intralocus sexual conflict[Title/Abstract] AND snp[Title/Abstract])) OR (intralocus sexual conflict[Title/Abstract] AND polymorphism[Title/Abstract])) OR (intralocus sexual conflict[Title/Abstract] AND variant[Title/Abstract])) OR (intralocus sexual conflict[Title/Abstract] AND allele[Title/Abstract])

Stage 2 Search term:
((((((((((((((((((

different[Title/Abstract] AND loci[Title/Abstract])) OR (sex different[Title/Abstract] AND gene[Title/Abstract])) OR (sex different[Title/Abstract] AND snp[Title/Abstract])) OR (sex different[Title/Abstract] AND polymorphism[Title/Abstract])) OR (sex different[Title/Abstract] AND variant[Title/Abstract])) OR (gender-dependent[Title/Abstract] AND locus[Title/Abstract])) OR (gender-dependent[Title/Abstract] AND loci[Title/Abstract])) OR (gender-dependent[Title/Abstract] AND gene[Title/Abstract])) OR (gender-dependent[Title/Abstract] AND snp[Title/Abstract])) OR (gender-dependent[Title/Abstract] AND polymorphism[Title/Abstract])) OR (gender-dependent[Title/Abstract] AND variant[Title/Abstract])) OR (male[Title/Abstract] AND female[Title/Abstract] AND opposite[Title/Abstract] AND locus[Title/Abstract])) OR (male[Title/Abstract] AND female[Title/Abstract] AND opposite[Title/Abstract] AND loci[Title/Abstract])) OR (male[Title/Abstract] AND female[Title/Abstract] AND opposite[Title/Abstract] AND gene[Title/Abstract])) OR (male[Title/Abstract] AND female[Title/Abstract] AND opposite[Title/Abstract] AND snp[Title/Abstract])) OR (male[Title/Abstract] AND female[Title/Abstract] AND opposite[Title/Abstract] AND polymorphism[Title/Abstract])) OR (male[Title/Abstract] AND female[Title/Abstract] AND opposite[Title/Abstract] AND variant[Title/Abstract])) OR (men[Title/Abstract] AND women[Title/Abstract] AND opposite[Title/Abstract] AND locus[Title/Abstract])) OR (men[Title/Abstract] AND women[Title/Abstract] AND opposite[Title/Abstract] AND loci[Title/Abstract])) OR (men[Title/Abstract] AND women[Title/Abstract] AND opposite[Title/Abstract] AND gene[Title/Abstract])) OR (men[Title/Abstract] AND women[Title/Abstract] AND opposite[Title/Abstract] AND snp[Title/Abstract])) OR (men[Title/Abstract] AND women[Title/Abstract] AND opposite[Title/Abstract] AND polymorphism[Title/Abstract])) OR (men[Title/Abstract] AND women[Title/Abstract] AND opposite[Title/Abstract] AND variant[Title/Abstract])) OR (boys[Title/Abstract] AND girls[Title/Abstract] AND opposite[Title/Abstract] AND locus[Title/Abstract])) OR (boys[Title/Abstract] AND girls[Title/Abstract] AND opposite[Title/Abstract] AND loci[Title/Abstract])) OR (boys[Title/Abstract] AND girls[Title/Abstract] AND opposite[Title/Abstract] AND gene[Title/Abstract])) OR (boys[Title/Abstract] AND girls[Title/Abstract] AND opposite[Title/Abstract] AND snp[Title/Abstract])) OR (boys[Title/Abstract] AND girls[Title/Abstract] AND opposite[Title/Abstract] AND polymorphism[Title/Abstract])) OR (boys[Title/Abstract] AND girls[Title/Abstract] AND opposite[Title/Abstract] AND variant[Title/Abstract])) OR (gender[Title/Abstract] AND opposite[Title/Abstract] AND allele[Title/Abstract])) OR (sex[Title/Abstract] AND opposite[Title/Abstract] AND allele[Title/Abstract])) OR (sex dependent[Title/Abstract] AND allele[Title/Abstract])) OR (sex different[Title/Abstract] AND allele[Title/Abstract])) OR (gender-dependent[Title/Abstract] AND allele[Title/Abstract])) OR (male[Title/Abstract] AND female[Title/Abstract] AND opposite[Title/Abstract] AND allele[Title/Abstract])) OR (men[Title/Abstract] AND women[Title/Abstract] AND opposite[Title/Abstract] AND allele[Title/Abstract])) OR (boys[Title/Abstract] AND girls[Title/Abstract] AND opposite[Title/Abstract] AND allele[Title/Abstract])

887



888
889
890 **Figure S1. Study reported effect allele frequencies and database allele frequencies are**
891 **strongly correlated.** The correlation between reported effect allele frequency and
892 frequencies for the same alleles obtained from the 1000 genomes database (0.94). Filled
893 circles represent disease risk/severity related variants while open circles represent complex
894 trait variants.
895



Figure S2. Relationship between study sample size and average extracted effect size across all studies.



Figure S3. Female effect size and male effect size are negatively correlated in SA alleles. Effect size (Cohen's D) of variants in females against effect size in males. Triangular points represent sex-opposite complex trait variants, circular points represent disease risk/severity variants.



Figure S4. The relationship between effect allele frequency and effect size ratio, grouped by trait class. Points to the right of the vertical dotted line have a greater negative effect than positive. **A.** Disease risk/severity variants. **B.** Complex traits. Point size is based on the variance of the effect size ratio, with smaller variance having larger point sizes and greater weighting in the statistical model.